Search bioRxiv⌕ Search

Biology subjects

Mertens, B.

Publications and source records attributed to Mertens, B..

2 recordsLinked to original sources

A Data-Driven Approach for the Development of a Time-informed Adverse Outcome Pathway-network for Cardiotoxicity of Environmental Chemicals

We present a novel Adverse Outcome Pathway (AOP) network for environmental chemical-induced cardiotoxicity using a bottom-up, data-driven AOP development approach. Mechanistic endpoints were systematically extracted from 339 in vitro and in vivo studies, yielding 1,759 Key Event (KE) entries and 4,938 Key Event Relationship (KER) entries, including information on experimental methods, essentiality evidence (intervention experiments demonstrating upstream-downstream dependence), and study metadata. After quality filtering (high risk of bias, confounding cytotoxicity in vitro, excessive toxicity or animal well-being concerns in vivo, and low-frequency observations), 112 unique KEs and 829 unique KERs supported by at least three independent observations were retained for network construction. Network analysis identified oxidative stress and mitochondrial dysfunction as dominant hub processes linking diverse upstream perturbations to downstream cardiomyocyte injury, inflammation, cardiac remodelling (fibrosis and hypertrophy), decreased cardiac contractility, and reduced left ventricular function. Incorporating exposure duration at the KER level enabled time-resolved pathway interpretation and demonstrated that KE timing is relationship-dependent, revealing temporal patterns not apparent when analysing KEs in isolation. This evidence-weighted, time-resolved AOP network can support endpoint prioritisation and exposure-window selection for non-animal method (NAM) test batteries and mechanistically informed cardiotoxicity assessment. SynopsisEnvironmental chemicals converge on shared stress and injury pathways that drive cardiac remodelling and ventricular dysfunction. A time-resolved AOP network helps prioritise endpoints and exposure windows for non-animal cardiotoxicity testing.

pharmacology and toxicology↗

Variability and uncertainty of data from genotoxicity Test Guidelines: What we know and why it matters.

This review comprehensively examines the variability and uncertainty associated with test guideline (TG)-conform genotoxicity data and explores the respective implications for the integration of non-animal-methods (NAMs) into regulatory frameworks. Historical amendments to OECD TGs are mapped to reveal the methods evolution that improves the scientific quality of the data but also explains data heterogeneity within available databases. An analysis of the major genotoxicity databases ECVAM, ISSMIC, and OASIS demonstrates substantial variability in genotoxicity calls. Using the EFSA genotoxicity database, which currently harbours the best-curated (meta-) data, we estimate that 22-77% of compounds exhibit similarity of replicate results below 85%, depending on the assay. The potentially most important variables statistically explaining variability and sensitivity were analysed. The practical limitations to identify them with high reliability and to define their optimum needs to be accepted as a qualitative baseline uncertainty. These findings underscore the necessity of contextualizing NAM performance evaluations within the intrinsic variability and uncertainty of animal and in vitro reference data. We propose that this variability is explicitly considered in the development and validation of NAM-based Integrated Approaches for Testing and Assessment (IATAs). This review provides a critical foundation for regulators and scientists aiming to enhance the acceptance and utility of NAMs in genotoxicity assessment.

pharmacology and toxicology↗